ResearchIn-Press PreviewOncologyTherapeutics Open Access | 10.1172/jci.insight.171916
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Zhao, D. in: JCI | PubMed | Google Scholar
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Guo, Y. in: JCI | PubMed | Google Scholar
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Wei, H. in: JCI | PubMed | Google Scholar
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Jia, X. in: JCI | PubMed | Google Scholar
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Zhi, Y. in: JCI | PubMed | Google Scholar
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by He, G. in: JCI | PubMed | Google Scholar
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Nie, W. in: JCI | PubMed | Google Scholar
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Huang, L. in: JCI | PubMed | Google Scholar
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Wang, P. in: JCI | PubMed | Google Scholar
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Laster, K. in: JCI | PubMed | Google Scholar
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Liu, Z. in: JCI | PubMed | Google Scholar
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Wang, J. in: JCI | PubMed | Google Scholar
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Lee, M. in: JCI | PubMed | Google Scholar |
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Dong, Z. in: JCI | PubMed | Google Scholar
1Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China
2China-US (Henan) Hormel Cancer Institute, Zhengzhou, China
3Linzhou Cancer Hosptial, Anyang, China
Find articles by Liu, K. in: JCI | PubMed | Google Scholar
Published April 23, 2024 - More info
Esophageal squamous cell carcinoma (ESCC) is the predominant form of esophageal cancer and is characterized by an unfavorable prognosis. To elucidate the distinct molecular alterations in ESCC and investigate therapeutic targets, we performed a comprehensive analysis of transcriptomic, proteomic, and phosphoproteomic data derived from 60 paired treatment-naive ESCC and adjacent non-tumor tissue samples. Additionally, we conducted a correlation analysis to describe the regulatory relationship between transcriptomic and proteomic processes, revealing alterations in key metabolic pathways. Unsupervised clustering analysis of the proteomic data stratified ESCC patients into three subtypes with different molecular characteristics and clinical outcomes. Notably, subtype III exhibited the worst prognosis and enrichment in proteins associated with malignant processes, including glycolysis and DNA repair pathways. Furthermore, translocase of inner mitochondrial membrane domain containing 1 (TIMMDC1) was validated as a potential prognostic molecule for ESCC. Moreover, integrated kinase-substrate network analysis using the phosphoproteome nominated candidate kinases as potential targets. In vitro and in vivo experiments further confirmed casein kinase II subunit alpha (CSNK2A1) as a potential kinase target for ESCC. These underlying data represent a valuable resource for researchers, which may provide better insights into the biology and treatment of ESCC.